Regeneron Pharmaceuticals (REGN) has risen sharply, recording gains of 5.53% in the past 4 weeks. However, the stock has corrected -1.2% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.11% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has recorded a 20-day Moving Average of 4.58% and the 50-Day Moving Average is 0%.
Regeneron Pharmaceuticals (NASDAQ:REGN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $367.88 and $363.45 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $375.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $373.81, notching a gain of 2.34% for the day. The total traded volume was 1,242,475 . The stock had closed at $365.27 on the previous day.
The company Insiders own 10.4% of Regeneron Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.47% . Institutional Investors own 75.15% of Regeneron Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -3.67%. In a related news, The Securities and Exchange Commission has divulged that Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, had unloaded 1,000 shares at an average price of $396.64 in a transaction dated on May 24, 2016. The total value of the transaction was worth $396,640.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.